Cargando…

Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC

INTRODUCTION: Randomized prospective studies on patients with metastatic non‐small‐cell lung cancers (NSCLCs) showed that anti‐programmed death‐1 (PD‐1) agents notably improved 2‐year overall survival (OS) rates, compared to docetaxel. NSCLC patients now receive nivolumab and irradiation, concurrent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lesueur, Paul, Escande, Alexandre, Thariat, Juliette, Vauléon, Enora, Monnet, Isabelle, Cortot, Alexis, Lerouge, Delphine, Danhier, Serge, Dô, Pascal, Dubos‐Arvis, Catherine, Chouaïd, Christos, Gervais, Radj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247050/ https://www.ncbi.nlm.nih.gov/pubmed/30311424 http://dx.doi.org/10.1002/cam4.1825

Ejemplares similares

Off-Label Use of Crizotinib as a Neoadjuvant Treatment for a Young Patient When Conventional Chemotherapy Gave No Benefits in Stage IIIA Non-Small Cell Lung Cancer
por: Dumont, Delphine, et al.
Publicado: (2017)

Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)
por: Martel-Lafay, Isabelle, et al.
Publicado: (2021)

Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer
por: Kissel, Manon, et al.
Publicado: (2019)

PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 “EPNEC” study
por: Arpin, Dominique, et al.
Publicado: (2020)

Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients
por: Lasnon, Charline, et al.
Publicado: (2013)

Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)
por: Vergnenègre, Alain, et al.
Publicado: (2019)

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
por: Raynaud, C., et al.
Publicado: (2015)

Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)
por: Christos, Chouaid, et al.
Publicado: (2012)

Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives
por: Césaire, Mathieu, et al.
Publicado: (2022)

Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)
por: Vergnenegre, Alain, et al.
Publicado: (2019)

Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)
por: Auliac, Jean-Bernard, et al.
Publicado: (2020)

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma
por: Bylicki, Olivier, et al.
Publicado: (2020)

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019
por: Auliac, Jean-Bernard, et al.
Publicado: (2020)

Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study)
por: Corre, Romain, et al.
Publicado: (2018)

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
por: Borget, Isabelle, et al.
Publicado: (2014)

Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14
por: Auliac, Jean-Bernard, et al.
Publicado: (2019)

A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)
por: LeCaer, H, et al.
Publicado: (2011)

Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis
por: Chouaid, Christos, et al.
Publicado: (2018)

Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined
por: Chouaïd, Christos, et al.
Publicado: (2020)

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
por: Maille, Elodie, et al.
Publicado: (2019)

Effect on eNOS/NO Pathway in MIRI rats with preconditioning of GFPC from Dang Gui Si Ni decoction
por: Qian, Guo-qiang, et al.
Publicado: (2014)

First-line management of advanced non-small-cell lung cancer: can we do better?
por: Chouaïd, Christos, et al.
Publicado: (2023)

Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC
por: Roborel de Climens, Ferréol, et al.
Publicado: (2021)

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis
por: Monnet, Isabelle, et al.
Publicado: (2021)

Pursuit or discontinuation of anti-PD1 after 2 years of treatment in long-term responder patients with non-small cell lung cancer
por: Ardin, Camille, et al.
Publicado: (2023)

Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
por: Dolladille, Charles, et al.
Publicado: (2020)

Tumour stage and gender predict recurrence and second primary malignancies in head and neck cancer: a multicentre study within the INHANCE consortium
por: Leoncini, Emanuele, et al.
Publicado: (2018)

Case Report About Fatal or Near-Fatal Hypersensitivity Reactions to Cetuximab: Anticetuximab IgE as a Valuable Screening Test
por: Dupont, Benoît, et al.
Publicado: (2014)

Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study
por: Assié, Jean-Baptiste, et al.
Publicado: (2022)

First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study
por: Amrane, Karim, et al.
Publicado: (2020)

RE: Role of Duplex Doppler US for Thyroid Nodules: Looking for the "Sword" Sign
por: Lacout, Alexis, et al.
Publicado: (2011)

Multicentric occurrence of multiple papillary thyroid carcinomas –HUMARA and BRAF mutation analysis
por: Nakazawa, Tadao, et al.
Publicado: (2015)

Image enhancement technology in bronchoscopy: a prospective multicentre study in lung cancer
por: van der Heijden, Erik H F M, et al.
Publicado: (2018)

A multicentre retrospective analysis on growth of residual hepatocellular adenoma after resection
por: Klompenhouwer, Anne J., et al.
Publicado: (2020)

Baseline monocyte and its classical subtype may predict efficacy of PD-1/PD-L1 inhibitor in cancers
por: Shao, Yilin, et al.
Publicado: (2021)

Impact of High-Grade Patterns in Early-Stage Lung Adenocarcinoma: A Multicentric Analysis
por: Bertoglio, Pietro, et al.
Publicado: (2022)

TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial
por: Nemunaitis, John, et al.
Publicado: (2015)

The impact of COVID-19 on lung cancer diagnostics – a multicentre comparison of 2019/2020 data
por: Navani, Neal, et al.
Publicado: (2021)

Hypothesised cutaneous sites of origin of stage III melanomas with unknown primary: A multicentre study
por: Clayton, Bethan, et al.
Publicado: (2022)

RE: Tips and Tricks of Percutaneous Gastrostomy Under Image Guidance in Patients with Limited Access
por: Marcy, Pierre-Yves, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_do6bkjuk234t94dj89bjgj20r2